Moderna, Inc. — Director's Dealing 2022

May 12, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2022-05-10

Reporting Person: Nader Francois (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-10	Common Stock	M	23100	$18.87	Acquired	23803	Direct
2022-05-10	Common Stock	S	3196	$136.10	Disposed	20607	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-05-10	Stock Option (Right to Buy)	$18.87	M	23100	Disposed	2029-12-10	Common Stock (23100)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 9, 2022.

F2: Represents the number of shares sold by the Reporting Person to cover the payment of the exercise price of the option.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.10 to $136.17. Full information regarding the number of shares sold at each separate price can be
furnished to the SEC staff upon request.

F4: This option is fully vested and exercisable.